Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Saurabh Saha, the Chief Executive Officer of Centessa Pharmaceuticals plc (NASDAQ:CNTA), a $2.15 billion market cap biotech company, has sold 55,000 ordinary shares of the company. The shares were sold at a weighted average price of $16.692, with the transactions taking place on March 20, 2025. The price per share ranged from $16.35 to $17.07, near the stock’s 52-week high of $19.09. Following the sale, Saha holds 276,017 shares directly. According to InvestingPro analysis, the stock currently appears overvalued based on its Fair Value assessment.
This sale was conducted under a Rule 10b5-1 trading plan that Saha adopted on May 16, 2024. Additionally, Saha holds 38,000 shares indirectly through a trust, where he and his spouse serve as trustees. The ordinary shares may be represented by American Depositary Shares, each representing one ordinary share. With the company’s earnings report due on March 27, InvestingPro data shows analysts maintain a strong buy consensus with price targets ranging from $26 to $36. InvestingPro subscribers have access to 8 additional key insights about CNTA’s financial health and growth prospects.
In other recent news, Centessa Pharmaceuticals has been the focus of several noteworthy developments. TD Cowen reiterated a Buy rating on Centessa, emphasizing the potential of its ORX750 treatment for sleep disorders. The analysts at TD Cowen highlighted the competitive efficacy and safety profile of ORX750, with Phase IIa results anticipated later this year. Additionally, Centessa announced the appointment of Stephen Kanes MD PhD as its new Chief Medical (TASE:BLWV) Officer, bringing extensive experience in neuroscience and drug development to the company. Dr. Kanes is expected to enhance Centessa’s efforts in advancing its orexin receptor 2 (OX2R) agonists for various disorders. Cowen research firm also initiated coverage of Centessa, assigning a Buy rating based on the promise of ORX750. The firm expressed confidence in the drug’s potential to address unmet needs in hypersomnia treatments. These recent developments underscore Centessa’s strategic focus on advancing its clinical trials and exploring broader applications for its treatments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.